Integra LifeSciences Holdings Corporation
IART · NASDAQ Global Select · USD
14,37USD
+0,95 (+7,08 %)Stand 9. Nov., 21:00
Nachbörslich14,370,00 (0,00 %)19:30 ET
Kennzahlen
- Eröffnung
- 13,66
- Vortag
- 13,42
- Tagesspanne
- 13,42 – 14,40
- 52 Wochen
- 8,70 – 20,49
- Volumen
- 1,04 Mio.
- Ø Volumen
- 982.692
- Börsenwert
- 1,12 Mrd. $
- KGV
- 85,6
- Gewinn je Aktie (TTM)
- 0,17
- Dividendenrendite
- 0,0 %
- Beta
- 1,3
- Nächste Zahlen
- 25. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 1,64 Mrd. | 1,61 Mrd. | 1,54 Mrd. | 1,56 Mrd. | 1,54 Mrd. |
| Herstellungskosten | 790,01 Mio. | 728,47 Mio. | 656,84 Mio. | 587,36 Mio. | 597,81 Mio. |
| Bruttogewinn | 845,23 Mio. | 882,06 Mio. | 884,74 Mio. | 970,31 Mio. | 944,64 Mio. |
| Forschung und Entwicklung | 98,97 Mio. | 115,38 Mio. | 104,19 Mio. | 101,19 Mio. | 93,05 Mio. |
| Vertrieb und Verwaltung | 699,7 Mio. | 716,98 Mio. | 656,64 Mio. | 616,32 Mio. | 637,45 Mio. |
| Operatives Ergebnis | 68,32 Mio. | 28,41 Mio. | 111,53 Mio. | 238,92 Mio. | 197,23 Mio. |
| EBITDA | −325,42 Mio. | 193,29 Mio. | 255,96 Mio. | 381,79 Mio. | 362,5 Mio. |
| Nettogewinn | −516,47 Mio. | −6,94 Mio. | 67,74 Mio. | 180,55 Mio. | 169,08 Mio. |
| Gewinn je Aktie (verwässert) | -6,73 | -0,09 | 0,84 | 2,16 | 1,98 |
Umsatz nach Segment
Produkte · FY 2025
- Codman Specialty Surgical1,2 Mrd. $73,41 %+4,97 %
- Tissue Technologies434,73 Mio. $26,59 %−6,89 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- UNITED STATES1,2 Mrd. $73,67 %+1,01 %
- Asia Pacific189,25 Mio. $11,57 %+7,16 %
- Europe162,67 Mio. $9,95 %+2,63 %
- Rest Of The World78,58 Mio. $4,81 %−5,03 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- 85,6
- Kurs-Umsatz-Verhältnis
- 0,7
- Kurs-Buchwert-Verhältnis
- 1,1
- PEG
- 0,1
- Bruttomarge
- 52,5 %
- Operative Marge
- 38,3 %
- Nettomarge
- 0,8 %
- Verschuldungsgrad
- 1,9
- EV/EBITDA
- 12,3
- Eigenkapitalrendite
- 1,2 %
- Kapitalrendite (ROIC)
- 11,4 %
- Free-Cashflow-Rendite
- 6,4 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 51,7 % | 54,8 % | 57,4 % | 62,3 % | 61,2 % |
| Operative Marge | 4,2 % | 1,8 % | 7,2 % | 15,3 % | 12,8 % |
| Nettomarge | −31,6 % | −0,4 % | 4,4 % | 11,6 % | 11,0 % |
| KGV | -1,8 | -251,4 | 50,1 | 25,7 | 33,5 |
| Kurs-Umsatz-Verhältnis | 0,6 | 1,1 | 2,2 | 3,0 | 3,7 |
| Kurs-Buchwert-Verhältnis | 0,9 | 1,1 | 2,1 | 2,6 | 3,4 |
| Verschuldungsgrad | 1,9 | 1,3 | 1,1 | 0,9 | 1,0 |
| Liquidität 3. Grades | 2,5 | 1,2 | 3,4 | 3,6 | 3,4 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 2,75 Mrd. | 3,48 Mrd. | 4,81 Mrd. | 5,83 Mrd. | 6,83 Mrd. |
| EV/EBITDA | -8,5 | 18,0 | 18,8 | 15,3 | 18,8 |
| Eigenkapitalrendite | −49,5 % | −0,4 % | 4,3 % | 10,0 % | 10,0 % |
| Kapitalrendite (ROIC) | 1,9 % | 0,3 % | 2,7 % | 5,5 % | 4,4 % |
| Free-Cashflow-Rendite | −4,7 % | 1,4 % | 2,1 % | 4,7 % | 4,7 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +1,5 % | +4,5 % | −1,0 % | +1,0 % | +12,4 % |
| Bruttogewinn | −4,2 % | −0,3 % | −8,8 % | +2,7 % | +11,0 % |
| Operatives Ergebnis | +140,5 % | −74,5 % | −53,3 % | +21,1 % | +30,3 % |
| Nettogewinn | −7.337,7 % | −110,3 % | −62,5 % | +6,8 % | +26,3 % |
| Gewinn je Aktie | −7.361,2 % | −110,7 % | −61,1 % | +9,1 % | +26,1 % |
| Freier Cashflow | −281,3 % | −65,8 % | −66,4 % | −17,8 % | +88,9 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 12Kaufen
- 12Halten
- 4Verkaufen
- 0Stark verkaufen
Kursziel
15,80
Durchschnitt · +9,95 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 1,64 Mrd. | 1,67 Mrd. | 1,73 Mrd. |
| Umsatz (Tief – Hoch) | 1,63 Mrd. – 1,65 Mrd. | 1,66 Mrd. – 1,71 Mrd. | 1,71 Mrd. – 1,76 Mrd. |
| Gewinn je Aktie (Ø) | 2,33 | 2,37 | 2,47 |
| Gewinn je Aktie (Tief – Hoch) | 2,32 – 2,34 | 2,30 – 2,45 | 2,00 – 2,94 |
| Analysten | 7 | 7 | 3 |
Letzte Änderungen
- UBS27. Okt. 2026Neutral
- Truist Securities26. Okt. 2026Hold
- Wells Fargo22. Okt. 2026Equal Weight
- Citizens22. Okt. 2026Market Outperform
- JP Morgan22. Okt. 2026Underweight
- Citigroup22. Okt. 2026Neutral
- BMO Capital22. Okt. 2026Market Perform
- Truist Securities14. Okt. 2026Hold
Quartalszahlen
Nächste Zahlen: 25. Feb. 2027| Okt. 2026 | Juli 2026 | Mai 2026 | Feb. 2026 | Okt. 2025 | Juli 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 0,56 | 0,48 | 0,41 | 0,79 | 0,43 | 0,43 | 0,43 | 0,86 |
| Gewinn je Aktie · Tatsächlich | 0,59 | 0,56 | 0,54 | 0,83 | 0,54 | 0,45 | 0,41 | 0,97 |
| Abweichung | +5,92 % | +16,55 % | +31,71 % | +5,06 % | +25,58 % | +4,65 % | −4,65 % | +12,79 % |
| Umsatz · Tatsächlich | 411,18 Mio. | 418,76 Mio. | 391,92 Mio. | 434,93 Mio. | 402,06 Mio. | 415,61 Mio. | 382,65 Mio. | 442,65 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
- 4. Jan. 20172:1
- 1. Juli 2015553:500
- 26. Mai 19981:2
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 97,09 %
- Investoren mit 13F-Meldung
- 213
Größte Investoren
- BLACKROCK, INC.13,67 %10,68 Mio.
- RUBRIC CAPITAL MANAGEMENT LP9,92 %7,75 Mio.
- INVESCO LTD.4,80 %3,75 Mio.
- VANGUARD PORTFOLIO MANAGEMENT LLC4,79 %3,74 Mio.
- MORGAN STANLEY4,60 %3,59 Mio.
- PARADIGM CAPITAL MANAGEMENT INC/NY4,40 %3,44 Mio.
- FULLER & THALER ASSET MANAGEMENT, INC.4,40 %3,44 Mio.
- STATE STREET CORP3,83 %2,95 Mio.
Insider-Geschäfte
- Caruso Andrea B1. Okt. 2026 · officer: CVP & CHROVerkauf0 Aktien
- Caruso Andrea B1. Okt. 2026 · officer: CVP & CHROVerkauf4375 Aktien · 43,39
- Caruso Andrea B1. Okt. 2026 · officer: CVP & CHROVerkauf2634 Aktien · 68,10
- Caruso Andrea B1. Okt. 2026 · officer: CVP & CHROVerkauf2674 Aktien · 65,11
- Caruso Andrea B1. Okt. 2026 · officer: CVP & CHROVerkauf3244 Aktien · 52,87
- Caruso Andrea B1. Okt. 2026 · officer: CVP & CHROVerkauf4634 Aktien · 36,22
- Caruso Andrea B1. Okt. 2026 · officer: CVP & CHROVerkauf6650 Aktien · 23,95
- Shinn Lesha R17. Sept. 2026 · officer: CVP, Chief Legal Officer & SecVerkauf0 Aktien
Vergleichbare Unternehmen
Über das Unternehmen
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
Führung
- Michael J. McBreenExecutive VP & Chief Commercial Officer
- Lea Daniels KnightExecutive Vice President & Chief Financial Officer
- Robert T. Davis Jr.Executive Vice President of Tissue Reconstruction and Distributed Technologies
- Harvinder SinghExecutive Vice President & President of International Business
- Michael D. HutchinsonExecutive Vice President, Chief Legal Officer & Secretary
- Jeffrey MosebrookSenior Vice President of Finance & Principal Accounting Officer
- CEO
- Stuart Essig
- Mitarbeitende
- 4.427
- Hauptsitz
- Princeton, NJ, US
- Sektor
- Healthcare
- Branche
- Medical - Devices
- Börsengang
- 16. Aug. 1995
- Website
- integralife.com
Nachrichten
- GlobeNewsWire · 6. Nov., 8:00Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference
- PRNewsWire · 5. Nov., 19:42INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
- GlobeNewsWire · 3. Nov., 18:10INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
- GlobeNewsWire · 30. Okt., 8:30Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting
- PRNewsWire · 29. Okt., 10:00INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
- GlobeNewsWire · 27. Okt., 17:59INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
- Seeking Alpha · 23. Okt., 12:21Integra LifeSciences: Progress Remains Frustratingly Slow, But Valuation Is Getting Interesting
- Business Wire · 23. Okt., 11:00Lost Money on Integra LifeSciences Holdings Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 21.2% Share Price Drop
- GuruFocus · 23. Okt., 11:00Lost Money on Integra LifeSciences Holdings Corporation Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 21.2% Share Price Drop
- Business Wire · 23. Okt., 9:00Did You Lose Money on Integra LifeSciences Holdings Corporation Stock? The Law Offices of Howard G.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.